International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	TECHNOLOGICAL AND REGENERATIVE INNOVATIONS IN THE MANAGEMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS): AN INTEGRATIVE REVIEW OF INTRAVESICAL AND CELLULAR THERAPIES
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5161
RECEIVED	14 February 2026
ACCEPTED	03 June 2026
PUBLISHED	12 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

TECHNOLOGICAL AND REGENERATIVE INNOVATIONS IN THE MANAGEMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS): AN INTEGRATIVE REVIEW OF INTRAVESICAL AND CELLULAR THERAPIES

Kinga Łysak *(Corresponding Author, Email: kinga.lys@vp.pl)*
Copernicus Memorial Hospital, Gdańsk, Poland
ORCID ID: 0009-0008-5002-4365

Kornelia Julia Fimiarz
Copernicus Memorial Hospital, Gdańsk, Poland
ORCID ID: 0009-0004-2867-9980

Irmina Grygutis
Copernicus Memorial Hospital, Gdańsk, Poland
ORCID ID: 0009-0008-2863-3471

Sonia Pawełkiewicz
Copernicus Memorial Hospital, Gdańsk, Poland
ORCID ID: 0009-0000-4087-5766

Iga Pyż
Copernicus Memorial Hospital, Gdańsk, Poland
ORCID ID: 0009-0008-0308-1308

Anna Łęczycka
Hospital of the Ministry of the Interior and Administration, Gdańsk, Poland
ORCID ID: 0009-0004-9068-5222

Iga Łysak
Medical University of Warsaw, Warsaw, Poland
ORCID ID: 0009-0005-9097-4670

ABSTRACT

Background: Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic inflammatory disorder characterized by urothelial barrier disruption, pelvic pain, urinary urgency and frequency, and significant psychosocial burden. This condition represents a significant therapeutic challenge due to urothelial barrier dysfunction and the "washout effect," which drastically shortens the exposure time of intravesically administered drugs.
Objectives: This review aims to comprehensively analyze recent (2020–2026) advances in regenerative and nanotechnological approaches designed to overcome traditional limitations in IC/BPS treatment. Emphasis is placed on evaluating the clinical efficacy, biological mechanisms, and social impact of next-generation therapies.
Methodology: A literature search was performed in PubMed, Scopus, MEDLINE, and Google Scholar for publications from 2020 to 2026 related to IC/BPS, focusing on thermosensitive hydrogels, nanocarriers, Platelet-Rich Plasma (PRP), amniotic-derived products, and gene-modulating therapies. Only peer-reviewed preclinical and clinical research relevant to innovative IC/BPS management was analyzed.
Results: Regenerative interventions, including Platelet-Rich Plasma (PRP) and Amniotic Bladder Therapy (ABT), demonstrate clinical symptom relief and improved Global Response Assessment (GRA) scores for up to 6 months. Network meta-analysis identifies PRP as highly effective for pain reduction ($SMD = -1.84$) compared to standard instillations. Advanced Drug Delivery Systems (DDS), such as thermosensitive hydrogels, extend intravesical drug residence to 5–7 days in preclinical models. Molecular precision therapies, specifically antisense Nerve Growth Factor (NGF) inhibitors and c-Jun N-terminal kinase (JNK) blockers, enable targeted intracellular modulation of neurogenic inflammation.
Conclusion: The transition from palliative barrier substitution to biohybrid platforms integrating sustained drug delivery with regenerative signaling represents the current therapeutic paradigm. Future implementation requires standardized clinical protocols and large-scale randomized trials to address existing translational gaps.

KEYWORDS

Interstitial Cystitis, Bladder Pain Syndrome, Regenerative Medicine, Platelet-Rich Plasma, Drug Delivery Systems, Amniotic Therapy, Social Impact, Innovative Technologies

CITATION

Kinga Łysak, Kornelia Julia Fimiarz, Irmina Grygutis, Sonia Pawełkiewicz, Iga Pyż, Anna Łęczycka, Iga Łysak. (2026) Technological and Regenerative Innovations in the Management of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): An Integrative Review of Intravesical and Cellular Therapies. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5161

Introduction

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic inflammatory condition of the lower urinary tract characterized by persistent pelvic pain, urinary urgency and frequency, and the absence of identifiable infection or structural abnormalities (Lim et al., 2025). It affects an estimated 2–6% of adult women and significantly impairs daily functioning, psychological well-being, and sleep quality, contributing to substantial social and economic burden (van Ginkel et al., 2024).

The pathophysiology involves epithelial dysfunction, immune activation, mast-cell sensitization, and neurogenic inflammation. Beyond disruption of the glycosaminoglycan (GAG) layer, contemporary evidence shows increased pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α and elevated nerve growth factor (NGF), which contribute to chronic pain and urothelial injury (Jafari & Rohn, 2023; Chen et al., 2025).

Conventional therapies, including hyaluronic acid, chondroitin sulfate, and dimethyl sulfoxide offer limited long-term benefit due to the "washout effect," which reduces intravesical drug contact time to 1–2 hours and decreases patient adherence (Doiron et al., 2025; Kumari & Goyal, 2022). Frequent instillations decrease adherence, increase healthcare utilization, and fail to address underlying molecular dysfunction (El Hefnawy et al., 2024).

Over the past five years, innovations in materials science and regenerative medicine have transformed the therapeutic landscape of IC/BPS. Locally acting regenerative therapies such as Platelet-Rich Plasma (PRP)

and Amniotic Bladder Therapy (ABT) directly promote epithelial healing by delivering growth factors, cytokines, and extracellular matrix (ECM) components that facilitate mucosal remodeling (Considine et al., 2024; Yu et al., 2025). Repeated PRP injections significantly reduce pain intensity and urinary frequency while improving the Global Response Assessment (GRA) score, with therapeutic benefits lasting up to six months.(Mourad et al., 2025). Likewise, micronized amniotic membrane injections have demonstrated anti-fibrotic and anti-inflammatory effects through inhibition of TGF-β1 pathways, supporting durable structural recovery in refractory patients (Madan et al., 2024).

Parallel to biological regeneration, technological innovations in drug delivery systems have sought to overcome the washout barrier. Thermosensitive hydrogels and nanocarrier platforms allow prolonged drug retention and facilitate controlled release of therapeutic agents such as lidocaine or anti-NGF oligonucleotides over several days (Song et al., 2022). Furthermore, molecular precision therapies such as antisense NGF inhibitors and JNK (c-Jun N-terminal kinase) pathway blockers represent a shift toward targeted intracellular modulation of inflammation and neuronal hyperexcitability (Taubert et al., 2024; Chen et al., 2025).

The convergence of smart biomaterials and regenerative medicine represents a promising paradigm for IC/BPS therapy. These integrated technologies aim not only to prolong drug exposure but also to actively restore urothelial integrity and normalize pathological signaling. As IC/BPS imposes substantial social and economic burden, innovative approaches with durable clinical benefit may significantly improve patient outcomes and reduce healthcare demand (van Ginkel et al., 2024).

The objective of this review is to synthesize and critically evaluate advanced local and regenerative approaches introduced between 2020 and 2026 for the management of IC/BPS, with particular emphasis on molecular mechanisms, clinical outcomes, and their broader social impact.

Technological Innovations in Intravesical Drug Delivery Systems (DDS)

Advanced drug delivery systems (DDS) have been developed to overcome the rapid washout of therapeutic agents, which historically limits urothelial exposure to less than two hours (Kumari & Goyal, 2022). Recent progress in materials engineering has driven the development of advanced drug delivery systems (DDS) that extend drug residence within the bladder and enable controlled release kinetics.

Among the most evidence-based technologies are thermosensitive hydrogels, specifically those utilizing hyaluronic acid and poloxamer 407 copolymers. These biomaterials exhibit a sol-to-gel transition at body temperature, remaining in liquid form at room temperature for catheter instillation before forming a biocompatible, mucoadhesive matrix within the bladder. Preclinical models indicate that these hydrogel platforms extend intravesical drug residence to 5–7 days, significantly enhancing the bioavailability of therapeutic payloads and reducing the required frequency of re-injections compared to standard aqueous solutions (Song et al., 2022; Kumari & Goyal, 2022).

Parallel to hydrogel development, liposomal and polymeric nanocarriers represent a critical advance in protecting fragile therapeutic compounds from urinary degradation (Janicki et al., 2015). Liposomal formulations facilitate transcellular uptake and have been effectively utilized to deliver lidocaine and botulinum toxin analogues with improved analgesic outcomes. Recent iterations of these nanocarriers, including cationic liposomes and polymeric nanoparticles, allow for the transport of fragile biological payload s such as antisense oligonucleotides and peptides (Saccà et al., 2021; Taubert et al., 2024).

The integration of these delivery technologies with molecular and regenerative agents marks a shift toward precision urology. While hydrogel-based systems focus on prolonged drug retention and stabilization, nanocarriers enhance the penetration of biological barriers, thereby bridging the gap between materials science and clinical regeneration. These technological foundations are essential for the efficacy of emerging biological interventions, ensuring that regenerative signals are maintained at the urothelial surface for sufficient durations to induce structural remodeling.

Regenerative Therapy: Platelet-Rich Plasma (PRP) and Amniotic Bladder Therapy

The transition in IC/BPS management from palliative symptom control toward active tissue reconstruction is driven by the application of Platelet-Rich Plasma (PRP) therapy. PRP utilizes autologous growth factors, including VEGF, PDGF, and EGF, to facilitate epithelial repair and suppress chronic inflammatory signaling (Li et al., 2022). Clinical data demonstrate a 76% success rate in patients receiving repeated intravesical injections, with therapeutic benefits sustained for up to six months. Submucosal administration has been associated with cystoscopic evidence of mucosal thickening and a significant reduction in hemorrhagic lesions (Yu et al., 2025; Mourad et al., 2025). A 2024 network meta-analysis identifies PRP as the most effective intervention for pain reduction, yielding a standardized mean difference (SMD) of -1.84, which significantly outperforms conventional pharmacologic instillations (Park et al., 2024).

Amniotic Bladder Therapy (ABT) represents a parallel advancement in regenerative urology, utilizing micronized amniotic or chorionic membranes to provide anti-fibrotic and pro-regenerative signaling. The primary biological mechanism involves the inhibition of the TGF-β1 pathway, which results in reduced tissue fibrosis and enhanced structural continuity of the bladder mucosa (Madan et al., 2024).

Longitudinal evaluations demonstrate significant reductions in pelvic pain and urinary frequency, with clinical efficacy maintained for at least six months following administration (Considine et al., 2024). The combination of biochemical trophic activity and immune modulation positions ABT as a next-generation alternative to conventional GAG-replenishment therapies. The safety profile and durability of this intervention suggest substantial socioeconomic benefits through the reduction of treatment frequency and healthcare resource utilization (Considine et al., 2024).

Molecular and Precision Therapies: Targeting Intracellular Signaling

The identification of specific intracellular pathways has enabled a transition toward precision pharmacology in IC/BPS management, moving beyond non-specific anti-inflammatory suppression. Central to this shift is the targeting of the Nerve Growth Factor (NGF) axis, as mucosal overexpression of NGF is a primary driver of C-fiber hyperexcitability and persistent pelvic pain sensitization. To counter this mechanism, intravesical antisense therapy utilizing vivo-morpholino oligonucleotides has been developed to bind specifically to NGF mRNA, blocking its translation at the cellular level. Preclinical models demonstrate that this gene-silencing approach significantly suppresses NGF expression and reduces urinary frequency, illustrating the potential for cell-specific molecular control within the urothelium (Chen et al., 2025) .

In parallel, the c-Jun N-terminal kinase (JNK) signaling cascade has emerged as a key mediator of urothelial apoptosis and the subsequent release of pro-inflammatory cytokines. The peptidic inhibitor Brimapiptide (XG-102) acts as a competitive inhibitor of JNK activation, thereby preventing apoptotic signaling and modulating neuroinflammation locally. When delivered via nanocarrier systems, Brimapiptide maintains therapeutic concentrations for up to 36 hours within the bladder environment, which enhances efficacy while minimizing the risk of systemic exposure. This integration of intracellular modulation with advanced delivery platforms defines the emerging domain of genetic and peptidergic medicine in urology (Taubert et al., 2024).

Additionally, ongoing research into endogenous mast-cell stabilizers such as Adelmidrol (a synthetic A LIAmide analogue of palmitoylethanolamide) demonstrates that down-regulation of mast-cell degranulation si gnificantly reduces bladder pain scores and cytokine release (Ostardo et al., 2018; D'Amico et al., 2020). Colle ctively, these molecular therapies signal a fundamental shift from non-specific anti-inflammation to targeted in tracellular pharmacology, addressing the neuro-immune mechanisms underlying chronic pain in IC/BPS.

Discussion

Recent developments in regenerative medicine and biomaterial-based platforms represent a significant shift in the therapeutic approach to Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Traditional GAG-layer replenishment therapies, although widely used, provide only short-term relief due to limited urothelial contact time and minimal impact on underlying inflammatory pathways (Kumari & Goyal, 2022).

The evidence synthesized in this review suggests that regenerative biologics, such as Platelet-Rich Plasma (PRP) and Amniotic Bladder Therapy (ABT), offer a superior alternative by selectively activating endogenous bioactive pathways to restore urothelial continuity and vascularization. These technologies have demonstrated the capacity to extend symptom-free intervals to six months. Both modalities improve Global Response Assessment (GRA) scores and reduce pelvic pain without increasing the risk of urinary retention, a common adverse effect with botulinum toxin A (Considine et al., 2024; Mourad et al., 2025; Yu et al., 2025).

Technological innovations play a key role in overcoming the “washout effect” that limits the effectiveness of conventional intravesical instillations. Thermosensitive hydrogels extend drug residence time to 5–7 days and enable stable delivery of anti-inflammatory or analgesic compounds (Song et al., 2022). Nanocarrier systems, including cationic liposomes and polymeric nanoparticles, further enhance intracellular drug uptake and protect biologic agents from urinary degradation (Taubert et al., 2024). Together, these systems form an essential foundation for precision urology by ensuring adequate drug exposure to support urothelial regeneration and reduce inflammation.

Molecular therapies represent another advancement in IC/BPS management. Antisense oligonucleotides targeting Nerve Growth Factor (NGF) decrease C-fiber hyperexcitability, while JNK inhibitors such as brimapiptide reduce apoptosis and cytokine release (Chen et al., 2025; Taubert et al., 2024). When paired with modern delivery platforms, these agents maintain effective intravesical concentrations and may prolong symptom remission.

Despite these clinical and technological promises, several critical barriers to widespread adoption remain. The current therapeutic landscape is characterized by a significant "bench-to-bedside" gap, driven by the absence of large-scale, multicenter randomized controlled trials (RCTs) and standardized treatment protocols. While regenerative therapies offer theoretical socio-economic benefits—including reduced treatment frequency and lower direct healthcare costs—these outcomes must be validated through rigorous cost-effectiveness and equity analyses. Furthermore, the complexity of the patient journey in IC/BPS necessitates that future research prioritizes patient-reported outcomes and long-term safety data over purely histological or animal-model successes. Until standardized dosing and delivery parameters are established, these innovative technologies risk remaining experimental rather than becoming the new clinical standard of care.

From a socio-clinical standpoint, regenerative and long-acting intravesical therapies offer potential benefits beyond symptom control. By reducing the frequency of clinic visits and improving quality of life, these innovations may decrease healthcare utilization and overall treatment burden (van Ginkel et al., 2024). Future research should therefore integrate clinical outcomes with patient-reported measures and cost-effectiveness assessments.

Taken together, current evidence suggests that regenerative biologics, molecular modulators, and advanced intravesical drug delivery systems represent complementary strategies capable of addressing both the biological and functional dimensions of IC/BPS. Continued progress will depend on conducting larger randomized trials, harmonizing preparation methods, and evaluating combination approaches to fully realize their therapeutic potential.

Conclusions

Innovative regenerative and biomaterial-based therapies represent a meaningful advancement beyond traditional symptomatic management of IC/BPS. Evidence from recent studies demonstrates that PRP, ABT, and targeted molecular inhibitors can promote urothelial healing, reduce inflammation, and provide sustained symptom relief for up to six months. Likewise, long-acting hydrogels and nanocarrier systems effectively address the long-standing “washout effect” by prolonging intravesical drug exposure and supporting the delivery of biologically active compounds.

These emerging therapies also have important implications for clinical practice and patient well-being. By improving treatment durability and reducing the frequency of intravesical procedures, regenerative and long-acting delivery platforms may lessen healthcare utilization, support better adherence, and enhance overall quality of life. Their favorable safety profiles further highlight their potential as practical alternatives for patients who do not respond to conventional therapies.

Despite these promising developments, further research is required to define standardized treatment protocols, determine long-term safety, and assess cost-effectiveness. Large multicenter randomized trials and harmonized preparation methods especially for PRP and ABT are necessary to guide clinical implementation. Future progress in IC/BPS management will likely rely on integrating regenerative biologics with advanced drug delivery technologies, offering a pathway toward more durable and mechanism-based therapeutic strategies.

Funding: This research received no external funding

Data availability statement: Data sharing is not applicable to this article

Conflict of interest: The authors declare no conflict of interest

Declaration of the use of generative AI and AI-assisted technologies in the writing process: In preparing this work, the authors used generative AI tools (ChatGPT) solely to support language editing and text formatting. After using these tools, the authors reviewed and edited the text as needed and accepted full responsibility for the content of the publication.

REFERENCES

1. D'Amico, R., Impellizzeri, D., Cuzzocrea, S., & Di Paola, R. (2020). ALIAmides update: Palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. *International Journal of Molecular Sciences, 21*(15), 5330. https://doi.org/10.3390/ijms21155330
2. Chen, Y. H., Chen, W. C., Liu, P. L., & Chen, H. Y. (2025). Intravesical instillation with vivo-morpholino nerve growth factor antisense therapy ameliorates acute interstitial cystitis/painful bladder syndrome-related urinary frequency in a rat model. *International Urogynecology Journal*. Advance online publication. https://doi.org/10.1007/s00192-025-06394-6
3. Considine, J., O'Hollaren, K., Radoiu, C., Madan, R., Liaw, A., & Dhar, N. (2024). Amniotic bladder therapy: Six-month follow-up treating interstitial cystitis/bladder pain syndrome. *International Urogynecology Journal, 35*(11), 2351–2357. https://doi.org/10.1007/s00192-024-06578-6
4. Doiron, R. C., Tadayon, B., Violette, P. D., Locke, J., Andrews, M., Nadeau, G., Gray, G., & Cox, A. (2025). 2025 Canadian Urological Association guideline: Selected treatment recommendations for interstitial cystitis/bladder pain syndrome. *Canadian Urological Association Journal, 19*(1), 10–22. https://doi.org/10.5489/cuaj.9182
5. El Hefnawy, A. S., Hasan, M. A. A., El Sawy, E., Abdel-Razik, M., & El-Tabey, N. (2024). Intravesical instillation of platelet-rich plasma for treatment of interstitial cystitis/bladder pain syndrome: A pilot study. *Urology Annals, 16*(2), 140–145. https://doi.org/10.1097/CU9.0000000000000156
6. Jafari, N. V., & Rohn, J. L. (2023). The urothelium: A multi-faceted barrier against a harsh environment. *Mucosal Immunology, 16*(1), 1–11. https://doi.org/10.1038/s41385-022-00565-0
7. Janicki, J. J., Gruber, M. A., & Chancellor, M. B. (2015). Intravesical liposome drug delivery and IC/BPS. *Translational Andrology and Urology, 4*(6), 617–623. https://doi.org/10.3978/j.issn.2223-4683.2015.08.03
8. Kumari, P., & Goyal, A. K. (2022). Challenges and opportunities in intravesical drug delivery approaches for the treatment of lower urinary diseases. *Journal of Controlled Release, 348*, 914–928. https://doi.org/10.1016/j.jddst.2024.106110
9. Lim, Y., Leslie, S. W., & O'Rourke, S. (2025). Interstitial cystitis/bladder pain syndrome. In *StatPearls*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK570588/
10. Madan, R., Radoiu, C., Vercnocke, J., Liaw, A., Lucas, S., Hamada, A., & Dhar, N. (2024). Amniotic bladder therapy in patients with interstitial cystitis/bladder pain syndrome. *The Journal of Urology, 211*(5S), e1163. https://doi.org/10.1097/01.JU.0001008584.88541.ff.05
11. Mourad, M. S., Tawfick, A., Kotb, M., Saleh, I. M., Salim, M. S., & Samir, Y. R. (2025). Efficacy and safety of submucosal intravesical injection of platelet-rich plasma in the treatment of interstitial cystitis/painful bladder syndrome. *International Urogynecology Journal*. Advance online publication. https://doi.org/10.1007/s00192-025-06324-6
12. Ostardo, E., Impellizzeri, D., Cervigni, M., Porru, D., Sommariva, M., Cordaro, M., Siracusa, R., Fusco, R., Gugliandolo, E., Crupi, R., Schievano, C., Inferrera, A., Di Paola, R., & Cuzzocrea, S. (2018). Adelmidrol + sodium hyaluronate in IC/BPS or conditions associated to chronic urothelial inflammation: A translational study. *Pharmacological Research, 134*, 16–30. https://doi.org/10.1016/j.phrs.2018.05.013
13. Park, J. J., Kim, K. T., Lee, E. J., Chun, J., Lee, S., Shim, S. R., & Kim, J. H. (2024). Current updates relating to treatment for interstitial cystitis/bladder pain syndrome: Systematic review and network meta-analysis. *Investigative and Clinical Urology, 65*(1), 12–23. https://doi.org/10.1186/s12894-024-01485-w
14. Song, S., Bi, H., Hao, G., Zheng, X., He, Y., Han, W., Song, S., & Zheng, A. (2022). Thermosensitive hydrogels as drug delivery systems: A comprehensive review. *Polymers, 14*(12), 2379. https://doi.org/10.3390/polym14122379
15. Taubert, E., van der Aa, F., & Heesakkers, J. (2024). Bladder pain syndrome AKA interstitial cystitis: A condition with severe unmet medical need: An exploration of brimapitide as a potential treatment opportunity. *Expert Opinion on Investigational Drugs, 32*(11), 1013–1022. https://doi.org/10.1097/MOU.0000000000001150
16. Van Ginkel, C., Martens, F., Scholtes, M., Heesakkers, J., & Janssen, D. A. W. (2024). Interstitial cystitis/bladder pain syndrome: Patient journey and quality of life. *Healthcare, 12*(4), 466. https://doi.org/10.3390/healthcare12040466
17. Yu, W. R., Jiang, Y. H., Jhang, J. F., & Kuo, H. C. (2025). Repeated intravesical injections of platelet-rich plasma are safe and effective in the treatment of interstitial cystitis/bladder pain syndrome. *Scientific Reports, 15*(1), 1023. https://doi.org/10.4103/tcmj.tcmj_166_24